NASDAQ:GILD

Gilead Sciences (GILD) Stock Price, News & Analysis

Gilead Sciences logo
$166.33 -0.20 (-0.12%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$167.22 +0.89 (+0.53%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Gilead Sciences Stock (NASDAQ:GILD)

Advanced

Key Stats

Today's Range
$165.80
▼
$170.24
50-Day Range
$144.23
▼
$174.48
52-Week Range
$116.88
▼
$176.58
Volume
7.55 million shs
Average Volume
6.36 million shs
Market Capitalization
$206.30 billion
P/E Ratio
N/A
Dividend Yield
1.97%
Price Target
$171.63
Consensus Rating
Moderate Buy

Company Overview

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19. The company conducts research and sells its medicines in the United States and internationally.

Gilead is led by chairman and chief executive officer Daniel O’Day, who joined the company in 2019. Through internal research and collaborations, the company continues to develop and expand treatments across its areas of focus.

AI Generated. May Contain Errors.

Gilead Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

GILD MarketRank™: 
3.194113524875 of 5 stars

Gilead Sciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 261st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 23 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Gilead Sciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Gilead Sciences has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Gilead Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Gilead Sciences are expected to grow in the coming year, from ($0.97) to $10.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gilead Sciences is -52.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gilead Sciences is -52.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gilead Sciences has a P/B Ratio of 15.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gilead Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.72% of the float of Gilead Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Gilead Sciences has a short interest ratio ("days to cover") of 3.18, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gilead Sciences has recently increased by 4.94%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Gilead Sciences pays a meaningful dividend of 1.97%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Gilead Sciences has been increasing its dividend for 10 years.

  • Dividend Sustainability

    Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 32.41% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

  • Read more about Gilead Sciences' dividend.
  • News Sentiment

    Gilead Sciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 53 news articles for Gilead Sciences this week, compared to 12 articles on an average week.
  • Search Interest

    Only 32 people have searched for GILD on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 92% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,799,137.00 in company stock.

  • Percentage Held by Insiders

    0.30% of the stock of Gilead Sciences is held by insiders.

  • Percentage Held by Institutions

    83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Gilead Sciences' insider trading history.
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
3 Pharmaceutical Stocks That Offer Safety and Growth (GILD)
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.
See More Headlines

GILD Stock Analysis - Frequently Asked Questions

Gilead Sciences' stock was trading at $122.74 at the start of the year. Since then, GILD shares have increased by 35.5% and is now trading at $166.3270.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.19 by $0.36. Gilead Sciences's revenue for the quarter was up 6.8% compared to the same quarter last year.
Read the conference call transcript
.

Gilead Sciences subsidiaries include MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and more.

Top institutional shareholders of Gilead Sciences include State Street Corp (4.91%), Dodge & Cox (1.76%), Boston Partners (0.53%) and Robeco Institutional Asset Management B.V. (0.28%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Deborah H Telman, Anthony Welters, Jeffrey Bluestone, Wettan Keeley M Cain and Kelly A Kramer.
View institutional ownership trends
.

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA) and Intel (INTC).

Company Calendar

Record date for 9/29 Dividend
9/15/2026
Ex-Dividend for 9/29 Dividend
9/15/2026
Dividend Payable
9/29/2026
Last Earnings
10/29/2026
Today
11/22/2026
Citi Annual Global Healthcare Conference 2026
12/01/2026
9th Annual Evercore ISI HealthCONx Conference
12/02/2026
Record date for 12/30 Dividend
12/15/2026
Ex-Dividend for 12/30 Dividend
12/15/2026
Dividend Payable
12/30/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/09/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GILD
CIK
882095
Employees
17,000
Year Founded
1987

Price Target and Rating

High Price Target
$200.00
Low Price Target
$127.00
Potential Upside/Downside
+3.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
29 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
16.44
P/E Growth
N/A
Net Income
$8.51 billion
Net Margins
-12.47%
Pretax Margin
-8.18%
Return on Equity
-1.85%
Return on Assets
-0.61%

Debt

Debt-to-Equity Ratio
1.84
Current Ratio
1.38
Quick Ratio
1.22

Sales & Book Value

Annual Sales
$29.44 billion
Price / Sales
7.01
Cash Flow
$10.46 per share
Price / Cash Flow
15.90
Book Value
$10.44 per share
Price / Book
15.93

Miscellaneous

Outstanding Shares
1,240,340,000
Free Float
1,236,618,000
Market Cap
$206.30 billion
Optionable
Optionable
Beta
0.35

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:GILD) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners